Congenica completes Series B financing round with investments from China-based BGI, Healthlink and Future Planet
Cambridge, UK, 27th April 2017 – Congenica, a world leader in clinical genomics software for inherited diseases, today announced completion of its recently announced Series B funding round with additional investments from new strategically important investors BGI Genomics (BGI), a recognized global leader in genomics, Healthlink Capital (Healthlink), another well-established China-based life-science investor and Future Planet Capital, a global innovation fund.
Campus research, innovation and engagement recognised at the 2022 Cambridge Independent Science and Technology Awards
The Cambridge Independent Science and Technology Awards took place on Wednesday evening at the Hinxton Hall Conference Centre. Campus teams, ...
13 May 2022Learn more
Birmingham 2022 Queen’s Baton Relay to visit Wellcome Genome Campus as full England route revealed
11 May 2022Learn more